OTC
55.08USD
+0.41 (+0.75%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
351.1B
P/E
—
EPS
—
Beta
0.34
52W range
37.51-60.85
Day range
54.46–55.42
Open
55.42
Prev close
54.67
Volume
112.8K
Avg volume
2.1M
Dividend
1.55
IPO
2003-08-20
https://www.globenewswire.com/news-release/2026/08/04/3338014/0/en/Nurix-Therapeutics-Announces-First-Patient-Enrolled-in-Registrational-Phase-3-DAYBreak-CLL-306-Trial-of-Bexobrutideg-in-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-Small-Lymph.html · 8/4/2026+0.40
https://www.zacks.com/stock/news/2951072/prta-stock-rises-nearly-11-in-six-months-what-s-driving-it?cid=CS-STOCKNEWSAPI-FT-analyst_blog|price_surge_/_plunge-2951072 · 7/9/2026+0.60
https://www.fool.com/investing/2026/07/09/vymi-vs-vigi-which-international-dividend-etf-is-b/ · 7/9/2026+0.00
https://www.zacks.com/stock/news/2948047/roche-reports-positive-results-from-head-to-head-study-on-nsclc-drug?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2948047 · 7/3/2026+0.90
https://www.zacks.com/stock/news/2945712/roche-gets-fda-priority-review-for-enspryng-in-thyroid-eye-disease?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2945712 · 6/30/2026+0.80
https://www.zacks.com/stock/news/2943766/nurix-therapeutics-nrix-soars-16-4-is-further-upside-left-in-the-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2943766 · 6/26/2026+0.40
https://www.zacks.com/stock/news/2941482/are-biosimilars-becoming-a-key-pillar-of-amgen-s-growth-story?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2941482 · 6/23/2026-0.40
https://www.zacks.com/stock/news/2939645/fda-accepts-roche-s-filing-for-lunsumio-velo-polivy-in-lbcl?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2939645 · 6/18/2026+0.80
https://seekingalpha.com/article/4914204-nurix-therapeutics-deal-with-roche-is-worth-betting-on · 6/11/2026+0.10
https://www.schaeffersresearch.com/content/news/2026/06/08/nurix-therapeutics-stock-pops-on-roche-partnership · 6/8/2026+0.20
https://www.zacks.com/stock/news/2932373/adct-stock-plunges-on-safety-concerns-despite-positive-lymphoma-data?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2932373 · 6/4/2026+0.00
https://www.businesswire.com/news/home/20260601485358/en/FDA-Accepts-New-Drug-Application-for-Genentech%E2%80%99s-Giredestrant-in-ER-Positive-Early-Stage-Breast-Cancer-the-First-and-Only-Oral-SERD-With-Positive-Phase-III-Results-in-the-Curative-Setting/ · 6/2/2026+0.60
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works